Mathematical Model Reveals HDV RNA Dynamics and HBV Reactivation During Lonafarnib Therapy
Researchers developed a mathematical model analyzing how lonafarnib, an investigational HDV drug, affects viral kinetics in 15 coinfected patients, finding rapid initial HDV decline followed by variable responses depending on combination therapy. The study reveals that HDV RNA has a half-life of approximately 1.26 days and that lonafarnib achieves 94% efficacy in inhibiting HDV production. The findings explain why HBV can reactivate when HDV levels drop, suggesting a suppressive relationship between the two viruses that has implications for treatment strategies.
Researchers analyzed serum samples from 15 patients with hepatitis B and D virus coinfection receiving lonafarnib-based therapy to understand viral kinetics during treatment. Using mathematical modeling, they found that lonafarnib monotherapy typically resulted in incomplete viral suppression or breakthrough, while combination therapy with ritonavir or pegylated interferon-alpha produced sustained biphasic HDV decline. The model estimated HDV RNA half-life at 1.26 days and lonafarnib treatment efficacy at 94% in inhibiting HDV production during the initial phase, increasing to 98.9% in later phases. A key finding was that HBV DNA production increased up to 4-fold when HDV levels fell below a critical threshold, suggesting HDV normally suppresses HBV replication. The model successfully reproduced observed viral kinetics across all treatment groups, providing mechanistic insights into how these viruses interact during antiviral therapy.
What's missing
The study's limitations regarding generalizability to larger patient populations, longer-term follow-up data beyond the study period, and clinical outcomes (such as HBsAg clearance or histological improvement) are not detailed in the abstract provided.
What different sources said
- arXiv physicsCenter
Mathematical Modeling of HDV RNA, HBV DNA, and HBsAg Dynamics during Lonafarnib-Based Therapy: Insights from the LOWR HDV-1 Study
Related
Topology-Aware Thermodynamics Improves DNA Probe Specificity Design
Researchers developed a new framework for designing DNA probes that accounts for the spatial organization of matched sequences, not just overall thermodynamic stability. Traditional methods rely on scalar measures like melting temperature and free energy, which miss how mismatches are distributed along the probe. The approach could improve diagnostic accuracy in applications like HPV detection and gene expression profiling.
Study Identifies Optimal Thermal Dose for Combining Focused Ultrasound with Immunotherapy in Tumors
Researchers used multimodal PET imaging to identify an optimal thermal dose range for focused ultrasound ablation that destroys tumor tissue while preserving conditions for immunotherapy delivery. The study found that excessive heating collapses blood vessels needed for antibody access, while insufficient heating fails to adequately reduce tumor burden. The findings could guide clinical design of combination treatments pairing thermal ablation with immunotherapies.
Plant MSH1 Protein Functions as Mismatch-Directed Nuclease for Organelle Genome Maintenance
Researchers have identified the precise mechanism by which the AtMSH1 protein in Arabidopsis plants recognizes and cleaves DNA mismatches and lesions, preventing mutations in organellar genomes. The protein combines a DNA mismatch recognition module with a nuclease domain that makes staggered cuts at specific positions relative to DNA damage. This discovery explains how plants maintain unusually low mutation rates in their mitochondrial and chloroplast DNA compared to other eukaryotes.